In Vitro and In Vivo Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The combination of chemotherapy with immunotherapy may offer an advantage over either therapy alone and provide a greater potential for total tumor eradication. Monocyte/macrophage-mediated tumor cell killing is a major mechanism of the host's defense against primary and/or metastatic neoplasia. We evaluated the tumoricidal activity against canine osteosarcoma cells of canine pulmonary alveolar macrophages (PAM) exposed in vitro to two recombinant canine (rc) cytokines (rcTNF alpha and rcIFN gamma). We also evaluated the in vivo tumoricidal activity of PAM from dogs treated with the macrophage activator, liposome-encapsulated muramyl tripeptide-phosphatidyl-ethanolamine (L-MTP-PE) alone or in combination with doxorubicin (DOX). This study demonstrated that rcTNF alpha and rcIFN gamma significantly enhance in vitro canine PAM cytotoxicity against canine osteosarcoma cells, and that PAM from dogs treated with DOX + L-MTP-PE have enhanced cytotoxic activity against osteosarcoma cells when compared to dogs treated with DOX or L-MTP-PE alone. These findings support the rationale for combining a chemotherapy agent with an immunotherapy agent for the treatment of metastatic disease, and suggest a role for TNF alpha and IFN gamma as agents for stimulating the antitumor activity of macrophages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kleinerman, E. S., Jia, S. F., Griffin, J., Seibel, N. L., Benjamin, R. S., & Jaffe, N. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.8.1310 · Cited by 157
Research works printed but not linked: 33
- Fidler IJ, 1985, Cancer Res, 45, 4714
- 10.1093/jnci/73.2.447 · doi:10.1093/jnci/73.2.447
- 10.1146/annurev.iy.02.040184.001435 · doi:10.1146/annurev.iy.02.040184.001435 · Paper page
- 10.1016/0952-7915(90)90031-B · DOI
- 10.1172/JCI110970 · doi:10.1172/jci110970
- Conkling PR, 1988, Cancer Res, 48, 5604
- Espinoza-Delgado I, 1990, J Immunol, 145, 1137, 10.4049/jimmunol.145.4.1137 · doi:10.4049/jimmunol.145.4.1137
- 10.1016/0165-2478(90)90174-O · DOI
- Demetri GD, 1992, Seminars in Oncol, 19, 362
- Van de Loosdrecht A, 1993, Cancer Res, 53, 4399
- Martin JH, 1994, Immunology, 81, 592
- 10.1016/S0171-2985(89)80049-X · DOI
- Zucker K, 1994, Coli. Lymph Cytokine Res, 13, 191
- Fogler WE, 1984, NY, 499
- 10.1073/pnas.78.3.1680 · DOI · Paper page
- Fidler IJ, 1982, J Biol Resp Modif, 1, 43
- 10.1007/BF00046339 · DOI · Paper page
- 10.3727/095535491820873740 · DOI
- 10.1007/BF01878149 · DOI
- 10.1016/S0022-5347(17)43178-8 · doi:10.1016/s0022-5347(17)43178-8
- 10.1093/jnci/81.24.1904 · doi:10.1093/jnci/81.24.1904
- Utsugi T, 1990, Cancer Res, 50, 2636
- Jia SF, 1991, Proc Am Assoc Cancer Res, 32, 227
- 10.1093/jnci/55.6.1265 · DOI · Paper page
- Rosenthal RC, 1989, Philadelphia, 63
- Stoychkov JN, 1979, Cancer Res, 39, 3014
- Ehrke MJ, 1984, Cancer Res, 44, 2497
- Arinaga S, 1986, Cancer Res, 46, 4213
- 1988, Cancer Res, 48, 5256
- Ehrke MJ, 1989, Semin Oncol, 16, 230
- 1993, Cancer Res, 53, 3986
- Vail DM, 1995, Am J Vet Res, 56, 282, 10.2460/ajvr.1995.56.03.282 · doi:10.2460/ajvr.1995.56.03.282
- 10.1089/cbr.1993.8.137 · doi:10.1089/cbr.1993.8.137
Cited by
Chou, A. J., Kleinerman, E. S., Krailo, M. D., Chen, Z., Betcher, D. L., Healey, J. H., Conrad, E. U., Nieder, M. L., Weiner, M. A., Wells, R. J., et al. (2009) · Cancer · doi:10.1002/cncr.24566 · Cited by 245
Morello, E., Martano, M., & Buracco, P. (2011) · The Veterinary Journal · doi:10.1016/j.tvjl.2010.08.014 · Cited by 172
“…administered with doxorubicin enhanced canine monocyte activation induced by doxorubicin or L-MTP-PE alone (Shi et al., 1993) and induced cytotoxic activity of pulmonary alveolar macrophages against OSA cells when compared to dogs treated with doxorubicin or L-MTP-PE alone (Kurzman et al., 1999).”
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
Canine Cancer: Strategies in Experimental Therapeutics
Thamm, D. H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01257 · Cited by 38
Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs
Brady, R. V., & Thamm, D. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176807 · Cited by 35
Metadata
- Authors
- Kurzman, I. D., Shi, F., Vail, D. M., & MacEwen, E. G.
- Venue
- Cancer Biotherapy and Radiopharmaceuticals
- Publisher
- SAGE Publications
- Published
- 1999-04
- Volume
- 14
- Issue
- 2
- Pages
- 121-128
- ISSN
- 1084-9785 (ISSN-L)
- 1557-8852
- OpenAlex
- W2043296164
- Cited by
- 46
- References
- 1
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro and In Vivo Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells. https://app.cochat.ai/papers/10.1089/cbr.1999.14.121
- The paper
- Kurzman, I. D., Shi, F., Vail, D. M., & MacEwen, E. G. (1999). In Vitro and In Vivo Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.1999.14.121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.